CI Global Health Sciences Corporate Class

Series F CAD
As of July 21, 2023 CI Global Health Sciences Corporate Class Y (NL 4924) merged into (NL 224)
 

Fund overview

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

Fund details

description of elementelement value
Inception date August 2000
Total net assets ($CAD)
As at 2023-08-31
$148.2 million
NAVPS
As at 2023-09-27
$35.1756
MER (%)
As at 2023-03-31
1.24
Management fee (%) 0.90
Asset class Sector Equity
Currency CAD
Minimum investment $500 initial/$25 additional
Distribution frequency Quarterly
Last distribution $0.6275

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

FUND CODES

F 224
A ISC 201
DSC SO* 701
LL SO 1701
E 16005
EF 15005
I 886
O 18005
P 90024
*No new purchases directly into switch only funds.

Performance2 As at 2023-08-31

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
3.34% 3.04% 3.54% 6.58% 13.77% 4.47% 2.70% 6.99% 7.16%
*Since inception date

Distribution history3

Payable date Total
2022-03-25 0.6275
2021-03-26 0.2155
2020-12-18 0.3483
2020-09-25 0.3458
2020-06-26 0.2577
Payable date Total
2020-03-20 0.6324
2019-12-13 0.3619
2019-09-27 0.4055
2019-06-21 0.3808
2019-03-22 0.6081

CI PREFERRED PRICING4

Investment amount Combined fee reduction
$100,000 and above 0.03%
$500,000 and above 0.06%
$1,000,000 and above 0.12%
$2,500,000 and above 0.20%
$5,000,000 and above 0.32%

Management team

First we'll display the Team Company and then the Team members
Greg Quickmire
Peter Hofstra

CI Global Health Sciences Corporate Class

Series F CAD
As of July 21, 2023 CI Global Health Sciences Corporate Class Y (NL 4924) merged into (NL 224)
 
Portfolio allocations5 As at 2023-08-31
Asset allocation (%)
  • US Equity 77.25
  • International Equity 21.49
  • Cash and Equivalents 1.25
  • Other 0.01
Sector allocation (%)
  • Healthcare 92.83
  • Exchange Traded Fund 3.48
  • Consumer Services 1.50
  • Cash and Cash Equivalent 1.25
  • Consumer Goods 0.81
  • Other 0.13
Geographic allocation(%)
  • United States 78.27
  • United Kingdom 7.04
  • Denmark 6.19
  • Switzerland 6.02
  • Germany 2.29
  • Other 0.13
  • Canada 0.06
Top holdings
Sector (%)
1. Eli Lilly and Co Drugs 8.27%
2. UnitedHealth Group Inc Healthcare Services 8.02%
3. Novo Nordisk A/S Cl B Drugs 6.19%
4. Humana Inc Healthcare Services 5.83%
5. Johnson & Johnson Drugs 5.41%
6. Merck & Co Inc Drugs 5.27%
7. AstraZeneca PLC Drugs 5.01%
8. Zoetis Inc Cl A Drugs 4.37%
9. Amgen Inc Drugs 3.61%
10. SPDR S&P Biotech ETF (XBI) Exchange Traded Fund 3.48%
11. Thermo Fisher Scientific Inc Healthcare Equipment 2.99%
12. Stryker Corp Healthcare Equipment 2.95%
13. Boston Scientific Corp Healthcare Equipment 2.81%
14. Alcon AG Healthcare Equipment 2.60%
15. Edwards Lifesciences Corp Healthcare Equipment 2.56%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.